

# The YODA Project

## Research Proposal Due Diligence Assessment

Part 1: General Information	
<b>YODA Project (Protocol) ID:</b>	2024 – 0352
<b>Date:</b>	April 4, 2024
<b>Product Name:</b>	Razadyne
<b>Therapeutic Area:</b>	Neuroscience
<b>Product Class:</b>	Alzheimer's Disease - Cholinesterase Inhibitors
<b>Condition(s) Studied:</b>	Alzheimer's Disease
<b>Protocol Number(s) and Title(s):</b>	<ol style="list-style-type: none"> <li>1. NCT00236574 - CR003145 // GAL-INT-11: A randomized Double blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients with Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease</li> <li>2. NCT00253214 - GAL-INT-10: Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation</li> </ol>
Part 2: Data Availability	
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments:	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments:	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments:	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments:	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments:	
Part 3: Data Availability Summary	
Based on the responses to the above Data Availability questions, the requested clinical trial data are available for a data sharing request.	Yes
Part 4: Proposal Review	
Question:	Response:
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	

**The YODA Project**  
**Research Proposal Due Diligence Assessment**